Community Resource Initiative

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026 - Merck.com DOR/ISL is the first non-INSTI, two-drug regimen to demonstrate non-inferiority and a similar safety profile at Week 48 to BIC/FTC/TAF in adults living with HIV-1 who had not previously received antiretroviral treatment DOR/ISL maintained virologic suppression at Week 96 in adults with virologically...

NEW: A phase 2 study from Gilead Sciences and Merck finds that once-weekly oral islatravir plus lenacapavir (ISL+LEN) maintained high rates of virologic suppression at 48 weeks in people with HIV-1 with no serious adverse events. These results suggest that ISL+LEN may offer a promising once-weekly treatment regimen that could help address adherence challenges in HIV care. https://bit.ly/4p6X5Ek

As we reflect on this past year at CRI, we are deeply grateful for the unwavering support of donors like you. Your generosity has given hope to Massachusetts residents facing the challenges of HIV and other infectious diseases. Together, we have continued our mission to provide life-saving access to treatment, including prevention medications, and striving for health equity for our most vulnerable neighbors. But our work does not stop here. Please consider making a donation today, Giving Tuesday.

https://crine.app.neoncrm.com/forms/end-of-year-2025?campaignId=286

Access to prevention remains a cornerstone of our work. This year, with your help, CRI expanded our outreach and education efforts, ensuring that more people have information about and access to effective prevention. These initiatives are vital in reducing new infections and promoting overall community health.

As we face new challenges and shifting federal funding, your unrestricted support is crucial. On Giving Tuesday, we invite you to make a year-end gift to CRI. Your generosity will ensure that everyone, regardless of circumstance, receives the care and dignity they deserve. Together, we can build a future free from HIV, full of hope and opportunity.

https://crine.app.neoncrm.com/forms/end-of-year-2025?campaignId=286

FDA approves powerful HIV drug that nearly eliminated spread in clinical trials